vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and American Strategic Investment Co. (NYC). Click either name above to swap in a different company.

American Strategic Investment Co. is the larger business by last-quarter revenue ($6.5M vs $3.9M, roughly 1.7× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -56.5%).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

Strategic Hotels & Resorts is an American REIT in the hospitality industry. It was publicly traded on the New York Stock Exchange as BEE. The company owns 18 luxury hotels, 17 of which are located in the United States and one of which is in Germany.

IRD vs NYC — Head-to-Head

Bigger by revenue
NYC
NYC
1.7× larger
NYC
$6.5M
$3.9M
IRD
Growing faster (revenue YoY)
IRD
IRD
+46.3% gap
IRD
-10.2%
-56.5%
NYC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRD
IRD
NYC
NYC
Revenue
$3.9M
$6.5M
Net Profit
$-6.7M
Gross Margin
Operating Margin
-4.8%
Net Margin
-103.4%
Revenue YoY
-10.2%
-56.5%
Net Profit YoY
53.0%
-0.7%
EPS (diluted)
$-2.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
NYC
NYC
Q4 25
$3.9M
$6.5M
Q3 25
$3.1M
$12.3M
Q2 25
$2.9M
$12.2M
Q1 25
$4.4M
$12.3M
Q4 24
$4.3M
Q3 24
$3.9M
Q2 24
$1.1M
Q1 24
$1.7M
Net Profit
IRD
IRD
NYC
NYC
Q4 25
$-6.7M
Q3 25
$-17.5M
$35.8M
Q2 25
$-7.4M
$-41.7M
Q1 25
$-8.2M
$-8.6M
Q4 24
Q3 24
$-7.5M
Q2 24
$-7.8M
Q1 24
$-7.1M
Operating Margin
IRD
IRD
NYC
NYC
Q4 25
-4.8%
Q3 25
-269.9%
Q2 25
-309.0%
-276.7%
Q1 25
-227.2%
-36.7%
Q4 24
Q3 24
-207.1%
Q2 24
-748.9%
Q1 24
-450.5%
Net Margin
IRD
IRD
NYC
NYC
Q4 25
-103.4%
Q3 25
-566.9%
291.4%
Q2 25
-257.5%
-340.9%
Q1 25
-187.5%
-69.8%
Q4 24
Q3 24
-194.6%
Q2 24
-698.3%
Q1 24
-415.3%
EPS (diluted)
IRD
IRD
NYC
NYC
Q4 25
$-2.14
Q3 25
$-0.25
$13.60
Q2 25
$-0.12
$-16.39
Q1 25
$-0.24
$-3.39
Q4 24
Q3 24
$-0.29
Q2 24
$-0.30
Q1 24
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
NYC
NYC
Cash + ST InvestmentsLiquidity on hand
$45.1M
$1.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.3M
$64.8M
Total Assets
$50.2M
$445.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
NYC
NYC
Q4 25
$45.1M
$1.3M
Q3 25
$30.8M
$3.4M
Q2 25
$32.4M
$5.3M
Q1 25
$41.8M
$7.1M
Q4 24
$30.3M
Q3 24
$36.6M
Q2 24
$41.4M
Q1 24
$47.2M
Stockholders' Equity
IRD
IRD
NYC
NYC
Q4 25
$15.3M
$64.8M
Q3 25
$6.0M
$71.4M
Q2 25
$17.5M
$35.5M
Q1 25
$5.1M
$77.1M
Q4 24
$6.7M
Q3 24
$34.3M
Q2 24
$40.6M
Q1 24
$46.1M
Total Assets
IRD
IRD
NYC
NYC
Q4 25
$50.2M
$445.2M
Q3 25
$36.1M
$448.1M
Q2 25
$38.7M
$464.0M
Q1 25
$48.2M
$499.4M
Q4 24
$36.9M
Q3 24
$40.4M
Q2 24
$44.8M
Q1 24
$51.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
NYC
NYC
Operating Cash FlowLast quarter
$-35.3M
$-7.8M
Free Cash FlowOCF − Capex
$-8.5M
FCF MarginFCF / Revenue
-131.4%
Capex IntensityCapex / Revenue
11.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
NYC
NYC
Q4 25
$-35.3M
$-7.8M
Q3 25
$-6.2M
$777.0K
Q2 25
$-10.3M
$-2.5M
Q1 25
$-9.0M
$-3.0M
Q4 24
$-25.6M
Q3 24
$-5.1M
Q2 24
$-7.3M
Q1 24
$-5.7M
Free Cash Flow
IRD
IRD
NYC
NYC
Q4 25
$-8.5M
Q3 25
$612.0K
Q2 25
$-3.0M
Q1 25
$-3.1M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
IRD
IRD
NYC
NYC
Q4 25
-131.4%
Q3 25
5.0%
Q2 25
-24.4%
Q1 25
-25.3%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
IRD
IRD
NYC
NYC
Q4 25
11.7%
Q3 25
1.3%
Q2 25
4.0%
Q1 25
0.6%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
IRD
IRD
NYC
NYC
Q4 25
Q3 25
0.02×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons